Validated Targets Sample Clauses

Validated Targets. For the avoidance of doubt, the Parties agree that Theravance's existing programs set forth on Schedule 1.36 are each Discovery Programs directed at Validated Targets.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Validated Targets. 38 Section 7.4. Astra Minimum Efforts. ............................... 38 Section 7.5. Commercialization .................................... 38 Section 7.6. Niche Products ....................................... 39 (iii)
Sample 1
Validated Targets. During the term of the Research Program and the Astra Development Program, Astra shall use [**] to utilize each Validated Target to discover and develop Hits, Leads, Candidate Drugs and Products. Such efforts [**] in connection with [**] that are at [**] and that are of [**] and [**]. Within thirty (30) days after the end of each calendar half-year during the term of the Research Program and the term of the Astra Development Program, Astra shall provide Millennium with a written report describing Astra's progress in using Validated Targets to discover and develop Hits, Leads, Candidate Drugs and Products. If Astra fails to satisfy its diligence obligations as set forth in this Section 7.3, as agreed between the Parties or determined pursuant to the dispute resolution process as set forth in Section 12.2, with respect to any Validated Target, then Astra's exclusive rights with respect to therapeutic products that are identified through the use of such Validated Target, and the Candidate Gene from which it was derived, [**] (with Millennium, either alone or in collaboration with others) as [**].
Sample 1
Validated Targets. Incyte shall have the right to select up to [**] Initial Validated Targets and up to [**] Supplemental Validated Targets, for a total of up to seven (7) Validated Targets, in the aggregate, in accordance with Section 3.1. Upon selection of seven (7) Validated Targets, in the aggregate, in accordance with Section 3.1, the Option rights granted to Incyte in Section 3.1 shall be deemed to have been exhausted and no further Option rights shall remain in effect (for clarity, regardless of the periods for which Option rights were granted).
Sample 1
Validated Targets. This Schedule 3.1.5 will be amended by the Parties on or after the date on which any Initial Research Target, Definitive Research Target or Extended Research Target becomes a Validated Target pursuant to Section 3.1. Schedule 7.4 Press Release For Immediate Release Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms WILMINGTON, Del. AND CAMBRIDGE, Mass. January 8, 2018 – Incyte Corporation (NASDAQ:INCY) and Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced today that the companies have entered into a target discovery, research collaboration and option agreement. Under the agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms (MPNs), and Incyte will receive options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to seven validated targets. Incyte will have exclusive worldwide rights to develop and commercialize any therapies under the collaboration that modulate those validated targets. “The discovery and development of novel therapeutic approaches to treat MPNs is an important area of focus at Incyte,” said Xxxx Xxxxx, Ph.D., Chief Scientific Officer of Incyte. “Through this collaboration, we believe that Syros’ gene control platform will allow us to advance our understanding of the underlying biology of MPNs and potentially uncover new molecular targets for drug discovery.” “Our gene control platform has broad applicability across diseases,” said Xxxxx Xxxxxxxx, M.D., Chief Executive Officer of Syros. “By working with Incyte, a leader in the discovery, development and commercialization of therapies for MPNs, we aim to leverage the promise of our platform to benefit patients with diseases beyond our current areas of focus. Meanwhile, we can continue advancing our own pipeline to achieve our long-term goal of building a fully integrated company with therapies that make a profound difference for patients.” Terms of the Agreement Under the terms of the agreement, Incyte will pay Syros $10 million upfront, including $2.5 million in cash and $7.5 million in prepaid R&D, and purchase a total of $10 million in Syros common stock at $12.61 per share. Should Incyte exercise all of its options under the agreement, Syros could receive up to $54 million from Incyte in target selection and option exercise fees. For products resulting from the collaboration ...
Sample 1
Validated Targets. During the term of the Program and the Lilly Development Program, Lilly shall diligently screen the Validated Targets to discover and develop Products. Lilly shall screen all Validated Targets within [**] of the date upon which the Validated Target milestone is paid to Millennium pursuant to Section 8.2. If a Validated Target is not screened within [**] of the payment of the milestone, then Lilly's exclusive right to use said Validated Target in the Field and the area of Oncology shall be converted into a co-exclusive right to use said Validated Target in the Field and the area of Oncology, subject to the other terms of this Section 7.2. Millennium may thereafter screen such a Validated Target in the Field and the area of Oncology, and retain rights to therapeutic leads found by Millennium using such a Validated Target, and proceed with the development of such compound on its own or sublicense the rights to such a compound and [**]. After a Validated Target is first screened, Lilly shall screen said Validated Target at least once every [**]. For each Validated Target, Lilly will be deemed to be diligent under this Section 7.2 so long as Lilly presents a compound arising from a screen against such Validated Target to [**] from the use of the Validated Target in a screen. In the event Lilly does not screen against a specific Validated Target within the time period set forth above, or does not present a compound arising from said screen to [**] within the time specified, Lilly's exclusive right to use said Validated Target in the Field and the area of Oncology shall be converted into a co-exclusive right to use said Validated Target in the Field and the area of Oncology, subject to the other terms of this Section 7.2. Millennium may thereafter screen such a Validated Target in the Field and the area of Oncology, provided, however, that such screening efforts shall be deemed to be a Non-Program Field Project subject to Lilly's rights under Section 5.2, except Lilly's rights thereto shall extend for [**] , Millennium may proceed with the development of such compound on its own or sublicense the rights to such a compound and [**]. Lilly shall not be required to continue to screen a Validated Target [**] from the Program in its development program (defined as a program that has been [**], or its successor) which (i) reacts with said Validated Target or which demonstrates the same clinical utility (and no significant clinical advantages) as a compound which reacts...
Sample 1
Validated Targets 
Sample 1
AutoNDA by SimpleDocs

Related to Validated Targets

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Milestone Schedule Please state the status and progress of each Milestone and identify any completed Milestone(s) for the previous calendar quarter.

  • Research Project 3.1 These Materials and Data will be used by Recipient's PI solely in connection with the Research Project, as named and described in the attached research application (insert Research Project name below):

  • Project Scope The physical scope of the Project shall be limited to only those capital improvements as described in Appendix A of this Agreement. In the event that circumstances require a change in such physical scope, the change must be approved by the District Committee, recorded in the District Committee's official meeting minutes, and provided to the OPWC Director for the execution of an amendment to this Agreement.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Project Specific Milestones In addition to the milestones stated in Section 212.5 of the Tariff, as applicable, during the term of this ISA, Interconnection Customer shall ensure that it meets each of the following development milestones:

  • Target Population The Grantee shall ensure that diversion programs and services provided under this grant are designed to serve juvenile offenders who are at risk of commitment to Department.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Sales Milestones On a Co-Co Product-by-Co-Co Product basis, Celgene shall make the following sales milestone payments to Jounce that are set forth below upon the first achievement by or on behalf of Celgene, its Affiliates or Sublicensees of the sales milestone events (“Sales Milestone Events”) set forth below with respect to sales of such Co-Co Product in the ROW Territory. Sales Milestone Event (Per Co-Co Product, ROW (i.e., ex-U.S.)) Milestone Payments (in $ millions) [***] [***] [***] [***]

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

Time is Money Join Law Insider Premium to draft better contracts faster.